Department of Physiology & Pathophysiology, School of Basic Medical Science, Peking University, Beijing, People's Republic of China.
Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Stem Cell Res Ther. 2018 Jan 23;9(1):16. doi: 10.1186/s13287-017-0767-z.
Deciphering molecular mechanisms underlying the division of hematopoietic stem cells (HSCs) and malignant precursors would improve our understanding of the basis of stem cell-fate decisions and oncogenic transformation.
Using a novel reporter of hematopoietic precursor, Evi1-GFP, we tracked the division of hematopoietic precursors in culture in real time.
First, we confirmed that Evi1-GFP is a faithful reporter of HSC activity and identified three dividing patterns of HSCs: symmetric renewal, symmetric differentiation, and asymmetric division. Moreover, we found that the cytokine and growth factor combination (STIF) promotes symmetric renewal, whereas OP9 stromal cells balance symmetric renewal and differentiation of HSCs ex vivo. Interestingly, we found that Tet2 knockout HSCs underwent more symmetric differentiation in culture compared with the wild-type control. Intriguingly, OP9 stromal cells reverse the phenotype of Tet2 knockout HSCs ex vivo. Furthermore, we demonstrated that Tet2 ;Flt3 acute myeloid leukemia (AML) precursors primarily underwent symmetric renewal divisions in culture. Mechanistically, we demonstrated that inhibiting DNA methylation can reverse the aberrant division phenotypes of Tet2 and Tet2 ;FLT3 precursors, suggesting that abnormal DNA methylation plays an important role in controlling (pre-)leukemic precursor fate decision ex vivo.
Our study exploited a new system to explore the molecular mechanisms of the regulation of benign and malignant hematopoietic precursor division ex vivo. The knowledge learned from these studies will provide new insights into the molecular mechanisms of HSC fate decision and leukemogenesis.
解析造血干细胞(HSCs)和恶性前体分裂的分子机制,将增进我们对干细胞命运决定和致癌转化基础的理解。
使用新型造血前体细胞报告基因 Evi1-GFP,我们实时追踪了培养中造血前体细胞的分裂情况。
首先,我们证实 Evi1-GFP 是 HSC 活性的忠实报告基因,并确定了 HSCs 的三种分裂模式:对称更新、对称分化和不对称分裂。此外,我们发现细胞因子和生长因子组合(STIF)促进对称更新,而 OP9 基质细胞在体外平衡 HSCs 的对称更新和分化。有趣的是,我们发现 Tet2 敲除 HSCs 在培养中经历更多的对称分化。有趣的是,OP9 基质细胞在体外逆转了 Tet2 敲除 HSCs 的表型。此外,我们证明 Tet2 ;Flt3 急性髓系白血病(AML)前体在培养中主要经历对称更新分裂。从机制上讲,我们证明抑制 DNA 甲基化可以逆转 Tet2 ;和 Tet2 ;FLT3 前体的异常分裂表型,表明异常的 DNA 甲基化在体外控制(前体)白血病前体命运决定中起重要作用。
我们的研究利用了一个新系统来探索调控良性和恶性造血前体细胞分裂的分子机制。从这些研究中获得的知识将为 HSC 命运决定和白血病发生的分子机制提供新的见解。